The White House quietly pulled Dr. Heidi Overton’s nomination to be Food and Drug Administration commissioner just before the Senate Health, Education, Labor and Pensions Committee was set to vote. Her name was literally struck through on the committee agenda — a fitting image for a nomination erased without a public roll call, and for the political dodge that followed. The administration says it lacked the votes. Sen. Bill Cassidy says the White House walked away rather than give pro‑life Republicans the assurances they requested. Both versions are convenient. Neither is honest accountability.
Withdrawal sparks a blame game
The administration’s story is short and tidy: not enough support, so we pulled the plug. Sen. Bill Cassidy, the HELP Committee chair, tells a different story — that Overton had a viable path and that pro‑life Republicans wanted assurances on the abortion‑pill review that the White House refused to provide. Which is it? We don’t know, because the vote never happened. No roll call, no record, no one forced to stand up and explain their choice. That means the White House can blame shy senators and senators can blame the White House — each gets to keep their political hands clean.
Why the fight mattered
This wasn’t just about a personality or a hearing soundbite. Overton’s confirmation hearings highlighted real policy fights — vaccines, vaping rules, and the high‑stakes safety review of the abortion drug mifepristone. The FDA has told courts it expects to finish gathering study results by mid‑December and to issue a report by March, so these are live policy questions. With the agency still led by an acting commissioner and the midterm losses shrinking the calendar for confirmations, the White House’s sudden withdrawal leaves a leadership vacuum and more chaos at a crucial agency.
Republicans must stop playing chicken
If Republicans want to run the show, they need to act like it. That means senators should put their demands on the record and the White House should either fight for nominees or nominate someone who can actually win a vote. Pulling a nominee quietly so nobody can tally the defectors is cowardice dressed up as strategy. If pro‑life senators want commitments, say what they are. If the administration won’t make them, name a different nominee who will. The public deserves to hear those debates, not watch them vanish under a strikethrough.
The next nominee will tell us a lot about priorities. Will the White House pick someone who can rally the GOP and protect conservative policy goals at the FDA, or will it keep sending names that split the party? Either way, the HELP Committee should stop letting confirmations die off the record. Vote, record the roll call, and let voters — not anonymous staff memos — decide who’s right. If President Donald Trump wants an FDA that follows his agenda, he needs nominees who can win, and a White House willing to engage the Senate like it cares. Otherwise, expect more crossed‑out names and even more political theater.

